What Is Hindsight Bias In Investing?
You’ve probably heard the expression “hindsight is 20/20.” That saying…
Sell
30
MREO Quote, Financials, Valuation and Earnings
Last price:
$2.37
Seasonality move
:
71.44%
Day range:
$2.33 - $2.44
52-week range:
$2.25 - $5.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.03x
Volume:
687.6K
Avg. volume:
1.3M
1-year change:
-20.88%
Market cap:
$364.6M
Revenue:
$10M
EPS (TTM):
-$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | -$0.01 | 1109.31% | -69.36% | $7.78 |
|
AUTL
Autolus Therapeutics PLC
|
$3M | -$0.24 | -85.98% | -7.1% | $10.21 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
NCNA
NuCana PLC
|
-- | -$2.20 | -- | -99.69% | $64.50 |
|
VRNA
Verona Pharma PLC
|
$33.5M | -$0.15 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
$2.35 | $7.78 | $364.6M | -- | $0.00 | 0% | -- |
|
AUTL
Autolus Therapeutics PLC
|
$1.62 | $10.21 | $431.1M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.59 | $17.97 | $1.1M | -- | $0.00 | 0% | 1.43x |
|
NCNA
NuCana PLC
|
$0.80 | $64.50 | $4.8M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$66.81 | $81.00 | $5.7B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.564 | -- | -- |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.987 | -- | 10.47x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 0.756 | -- | 1.20x |
|
NCNA
NuCana PLC
|
-- | 0.645 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | -0.759 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | -$9.1M | -- | -- | -- | -$7.5M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$75.9M | -51.91% | -51.91% | -196479.31% | -$61.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
Mereo BioPharma Group PLC vs. Competitors
-
Which has Higher Returns MREO or AUTL?
Autolus Therapeutics PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -95193.1%. Mereo BioPharma Group PLC's return on equity of -- beat Autolus Therapeutics PLC's return on equity of -51.91%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- AUTLAutolus Therapeutics PLC-- -$0.09 $427.3M -
What do Analysts Say About MREO or AUTL?
Mereo BioPharma Group PLC has a consensus price target of $7.78, signalling upside risk potential of 231.03%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.21 which suggests that it could grow by 530.32%. Given that Autolus Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Autolus Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is MREO or AUTL More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.067, suggesting its more volatile than the S&P 500 by 106.723%.
-
Which is a Better Dividend Stock MREO or AUTL?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or AUTL?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $29K. Mereo BioPharma Group PLC's net income of -$15M is higher than Autolus Therapeutics PLC's net income of -$27.6M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M AUTLAutolus Therapeutics PLC-- -- $29K -$27.6M
-
Which has Higher Returns MREO or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About MREO or BDRX?
Mereo BioPharma Group PLC has a consensus price target of $7.78, signalling upside risk potential of 231.03%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 1037.84%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is MREO or BDRX More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.
-
Which is a Better Dividend Stock MREO or BDRX?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BDRX?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$15M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 1.43x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M BDRXBiodexa Pharmaceuticals PLC1.43x -- -- --
-
Which has Higher Returns MREO or NCNA?
NuCana PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About MREO or NCNA?
Mereo BioPharma Group PLC has a consensus price target of $7.78, signalling upside risk potential of 231.03%. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 7962.5%. Given that NuCana PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe NuCana PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 NCNANuCana PLC1 1 0 -
Is MREO or NCNA More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.789%.
-
Which is a Better Dividend Stock MREO or NCNA?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or NCNA?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$15M is lower than NuCana PLC's net income of -$836.1K. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns MREO or VRNA?
Verona Pharma PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -92.29%. Mereo BioPharma Group PLC's return on equity of -- beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About MREO or VRNA?
Mereo BioPharma Group PLC has a consensus price target of $7.78, signalling upside risk potential of 231.03%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 21.24%. Given that Mereo BioPharma Group PLC has higher upside potential than Verona Pharma PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 VRNAVerona Pharma PLC5 0 0 -
Is MREO or VRNA More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.803%.
-
Which is a Better Dividend Stock MREO or VRNA?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or VRNA?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. Mereo BioPharma Group PLC's net income of -$15M is higher than Verona Pharma PLC's net income of -$33.8M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Will Chevron Acquire Hess?
Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
29
UNF alert for Mar 26
UniFirst [UNF] is up 0.05% over the past day.
Sell
30
KEQU alert for Mar 26
Kewaunee Scientific [KEQU] is up 1.01% over the past day.
Buy
82
EPAC alert for Mar 26
Enerpac Tool Group [EPAC] is down 0.53% over the past day.
